Auxilium Pharmaceuticals — Investor Presentation (June 2010)
32 slides from Auxilium Pharmaceuticals's investor presentation, Jun 8, 2010
Slide 1: June 2010
June 2010 (NASDAQ: AUXL) Exhibit 99.1
Slide 2: Safe Harbor Statement
Safe Harbor Statement We will make various remarks during this presentation that constitute “forward-looking statements” for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995, including statements regarding the opportunities to build shareholder value;
Slide 3: Opportunities to Build Shareholder Value
Opportunities to Build Shareholder Value ® Note: Seeking partners for Transmucosal film product candidates
Slide 4: XIAFLEX transforming treatment
IAB colagenase clostridium histolyticum TRANSFORMING TREATMENT oc esasr-an5-01 Rconly collagenase clostridium histolyticut (0.9 mg per vial for injection for intralesional use ‘Attention: Dispense the e- Medication Guide to each: sp de
Slide 5: XIAFLEX – Unique, Late-Stage, Blockbuster Opportunity
XIAFLEX – Unique, Late-Stage, Blockbuster Opportunity • Potential to be the only effective non-surgical treatment for two high unmet needs: Approved on February 2, 2010 for Dupuytren’s Contracture in U.S. Promising phase IIb results in Peyronie’s disease • Well-characterized mode of action • Worldwi
Slide 6: Dupuytren's Contracture is Debilitating for Patients
Dupuytren’s Contracture is Debilitating for Patients • Excessive collagen deposition in fascia of hand • Nodules represent early, active form • Cords develop over time, are palpable, and result in contractures • Quality of life and daily activities can be significantly affected • Surgery has been th
Slide 7: Treatment Options Historically Limited to Invasive Surgery
Treatment Options Historically Limited to Invasive Surgery with Significant Recuperation or Are Unapproved and Ineffective • Surgery • Needle fasciotomy/ aponeurotomy • Amputation • Non-surgical options > Splinting > Physical therapy > Corticosteroids
Slide 8: XIAFLEX Offers the First Nonsurgical Treatment for Dupuytren's Contracture
XIAFLEX Offers the First Nonsurgical Treatment for Dupuytren’s Contracture
Slide 9: A Significant Number of Patients Benefited from Treatment with XIAFLEX
A Significant Number of Dupuytren’s Contracture Patients Benefited from Treatment with XIAFLEX
Slide 10: Early Intervention with XIAFLEX May Be the Most Effective Approach
Early Intervention with XIAFLEX May Be the Most Effective Treatment Approach Hurst et al. NEJM 2009 N=248 N=125 Keith Denkler, M.D. Plast. Reconstr. Surg., 115802, 2005 Dupuytren’s Fasciectomies in 60 Consecutive Digits using lidocaine with epinepherine and no tournequet
Slide 11: XIAFLEX Was Well-Tolerated in Phase III Studies
XIAFLEX Was Well-Tolerated in Phase III Studies • Most treatment related adverse events were mild or moderate in intensity and resolved without intervention within a median of 10 days across studies • Serious Adverse Events possibly related to treatment were limited in number (10 in total; 0.39% of
Slide 12: Contracture Recurrence Affects Patients
Contracture Recurrence Affects Patients • The earliest reports of recurrence for surgery were seen in 22% of female and 19% of male Dupuytren’s contracture patients at a mean of months following fasciectomy . Additionally, a rate of up to 34% has been reported within the first years following surger
Slide 13: Two Year Recurrence Rate of 19.3% for XIAFLEX
Two Year Recurrence Rate of 19.3% for XIAFLEX ® in Dupuytren’s Contracture All Joints MP Joints PIP Joints Patients from All Phase III Studies (n=950) 1,568 Patients Enrolled in Extension Study (n=634) 1,065 Patients Successfully Treated and Enrolled in Extension Study (n=474) 619* 449* Joints with
Slide 14: Launch Update Through May 2010
Launch Update Through May 2010
Slide 15: Key Objectives for U.S. XIAFLEX Launch in 2010
Key Objectives for U.S. XIAFLEX Launch in 2010 • Position XIAFLEX as a paradigm changing non-surgical treatment alternative for physicians, payers and patients • Achieve high awareness among targeted physicians and diagnosed patients • Get targeted physicians through the sales cycle – from interest
Slide 16: First Commercial Patient Injected
First Commercial Patient Injected Patient with 50 degree MP cord pre injection Post manipulation – Able to lay hand flat on table Post injection and pre manipulation Individual results may vary. See Hurst et al. NEJM 2009
Slide 17: Targeting the Eligible Patient Population Should Drive Market Development
We Believe that Targeting the Eligible Patient Population Should Drive Development of the U.S. Market to Its Full Potential 1. Dupuytren’s Disease – Tubiana, LeClerq, Hurst, Badalamente, Mackin 2. SDI Claims Data Based Projections 3. Medicare Data Based Projections (BESS database used, Medicare 5% d
Slide 18: XIAFLEX Launch Strategy is Tailored to Customer Needs
XIAFLEX Launch Strategy is Tailored to Customer Needs • ~ 7,000 target physicians – Hand surgeons, plastic surgeons, orthopedic surgeons, general surgeons, rheumatologists • ~ 100 field based personnel – Sales reps, sales managers, and reimbursement specialists • Medical science liaisons – Key opini
Slide 19: Access to Physicians
Access to Physicians • Since launch in late March, majority of physicians called upon receptive to meeting with our sales reps • Significant time being spent with office staff – Calls can typically run from 30 minutes to 3 hours • Changing a treatment paradigm takes time
Slide 20: Unique Sales Cycle for Targeted Physicians
Unique Sales Cycle for Targeted Physicians Physician Interest, Training & Enrollment Successful XIAFLEX XPERIENCE
Slide 21: Changing Treatment Paradigm and Reimbursement Cycle May Drive Adoption
Changing Treatment Paradigm and Reimbursement Cycle May Drive Physician Adoption Rate Prior to treatment decision Physician must go through: •Awareness •Interest •Training / Enrollment into XIAFLEX XPERIENCE program •Reimbursement education / comfort •Patient Identification / counseling 11 – 21 week
Slide 22: Reimbursement Processes Are New to Target Physicians
Reimbursement Processes Are New to Target Physicians • Accounts need customized support every step of the way • Miscellaneous J and CPT codes being used; component and bundled approaches are being accepted • C-code for institutional use will be effective July 1, 2010 • CMS has recommended a J-Code f
Slide 23: Over 1,400 physicians and 900 sites enrolled in XIAFLEX XPERIENCE
Leading Indicators Trending Positively - Over 1,400 physicians and 900 sites have enrolled in XIAFLEX XPERIENCE program
Slide 24: Leading Indicators - Cumulative Call Center Volume
Leading Indicators Trending Positively - Cumulative Call Center Volume Note: SP = Specialty Pharmacy; IV = Insurance Verification
Slide 25: Leading Indicators - Sites that have ordered XIAFLEX
Leading Indicators Trending Positively - Sites that have ordered XIAFLEX
Slide 26: Approximately 87% of insured lives have access to XIAFLEX
Approximately 87% of insured lives have access to XIAFLEX
Slide 27: Out of Pocket Costs In Line With Our Expectations
Out of Pocket Costs In Line With Our Expectations Source: Data processed by AUXL call center through May 31, 2010 A significant portion of patients paying 20% and above have a secondary insurance, which may cover a portion of this cost % Of Treatment Cost Paid by Patient
Slide 28: Distribution Network is Operating Smoothly
Distribution Network is Operating Smoothly
Slide 29: We Believe Launch Strategy Is Sound
We Believe Launch Strategy Is Sound: • Product efficacy and safety are consistent with clinical data • Access to targeted physicians is good. • Usage is characterized by “test driving”, which is typical for paradigm changing treatment • Payers willing to provide access to drug and procedures • All d
Slide 30: Auxilium's Plan to Provide Visibility on XIAFLEX Launch
Auxilium’s Plan to Provide Visibility on XIAFLEX Launch • We will pre-release Q2 revenues in early July • On Q2 earnings call we will provide revenue guidance for Q3 • We will continue to provide quarterly revenue guidance through 2010
Slide 31: Strategic Corporate Priorities in 2010
Strategic Corporate Priorities in 2010 • Execute the launch in the U.S. for XIAFLEX in Dupuytren’s contracture; • Support Pfizer in the ongoing regulatory review of the EMA Dupuytren’s submission and prepare for their potential EU approval; • Commence phase III for XIAFLEX in Peyronie’s disease, ass
Slide 32: Opportunities to Build Shareholder Value
Opportunities to Build Shareholder Value ® ® Note: Seeking partners for Transmucosal film product candidates
Auxilium Pharmaceuticals — Investor Presentation (June 2010) on 6ix